UA90875C2 - Лекарственные формы пролонгированного действия, которые содержат ранолазин - Google Patents

Лекарственные формы пролонгированного действия, которые содержат ранолазин

Info

Publication number
UA90875C2
UA90875C2 UAA200707605A UAA200707605A UA90875C2 UA 90875 C2 UA90875 C2 UA 90875C2 UA A200707605 A UAA200707605 A UA A200707605A UA A200707605 A UAA200707605 A UA A200707605A UA 90875 C2 UA90875 C2 UA 90875C2
Authority
UA
Ukraine
Prior art keywords
sustained release
ranolazine
pharmaceutical formulations
release pharmaceutical
novel
Prior art date
Application number
UAA200707605A
Other languages
English (en)
Ukrainian (uk)
Inventor
Сриконда Састри
Джанаки Найшадхам
Original Assignee
СиВи СЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиВи СЕРАПЬЮТИКС, ИНК. filed Critical СиВи СЕРАПЬЮТИКС, ИНК.
Publication of UA90875C2 publication Critical patent/UA90875C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Данное изобретение касается лекарственной формы ранолазина пролонгированного действия, которая содержит приблизительно 35-49 % ранолазина, зависимое от рН вяжущее, независимое от рН вяжущее и фармацевтически приемлемые наполнители, предназначенной для лечения сердечно-сосудистого заболевания.
UAA200707605A 2005-01-06 2006-01-05 Лекарственные формы пролонгированного действия, которые содержат ранолазин UA90875C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64216805P 2005-01-06 2005-01-06

Publications (1)

Publication Number Publication Date
UA90875C2 true UA90875C2 (ru) 2010-06-10

Family

ID=36648222

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200707605A UA90875C2 (ru) 2005-01-06 2006-01-05 Лекарственные формы пролонгированного действия, которые содержат ранолазин

Country Status (16)

Country Link
US (1) US20060177502A1 (ru)
EP (1) EP1841411A2 (ru)
JP (1) JP2008526879A (ru)
KR (1) KR20070093988A (ru)
CN (1) CN101098682A (ru)
AU (1) AU2006203890A1 (ru)
BR (1) BRPI0606403A2 (ru)
CA (1) CA2593593A1 (ru)
GE (1) GEP20094784B (ru)
IL (1) IL184460A0 (ru)
MX (1) MX2007008162A (ru)
NO (1) NO20074037L (ru)
RU (1) RU2384332C2 (ru)
UA (1) UA90875C2 (ru)
WO (1) WO2006074398A2 (ru)
ZA (1) ZA200705530B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4546824B2 (ja) 2002-05-21 2010-09-22 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を処置する方法
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EP2139480A1 (en) * 2007-04-12 2010-01-06 CV Therapeutics Inc. Ranolazine for enhancing insulin secretion
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
BRPI0721741A2 (pt) * 2007-05-31 2013-02-13 Cv Therapeutics Inc mÉtodo de tratamento de diabetes
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016144855A1 (en) * 2015-03-07 2016-09-15 Innophos, Inc. Leavening composition to replace aluminum based leavening acids
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN110859843A (zh) * 2019-12-17 2020-03-06 卓和药业集团有限公司 一种治疗动脉硬化合并心绞痛的药物组合物及制备方法
CN111000818A (zh) * 2020-01-04 2020-04-14 东莞市东阳光仿制药研发有限公司 一种雷诺嗪组合物及其制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6242918A (ja) * 1985-08-20 1987-02-24 Kaken Pharmaceut Co Ltd 持続性製剤
AU622254B2 (en) * 1989-01-03 1992-04-02 Sterling Drug Inc. Controlled-release, low dose aspirin
ATE223218T1 (de) * 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
US5527545A (en) * 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5403593A (en) * 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
JP4546824B2 (ja) * 2002-05-21 2010-09-22 ギリアード・パロ・アルト・インコーポレイテッド 糖尿病を処置する方法

Also Published As

Publication number Publication date
WO2006074398A2 (en) 2006-07-13
JP2008526879A (ja) 2008-07-24
IL184460A0 (en) 2007-10-31
NO20074037L (no) 2007-08-03
WO2006074398A3 (en) 2007-02-22
AU2006203890A1 (en) 2006-07-13
CA2593593A1 (en) 2006-07-13
US20060177502A1 (en) 2006-08-10
ZA200705530B (en) 2008-10-29
KR20070093988A (ko) 2007-09-19
CN101098682A (zh) 2008-01-02
RU2384332C2 (ru) 2010-03-20
BRPI0606403A2 (pt) 2009-06-23
GEP20094784B (en) 2009-09-25
EP1841411A2 (en) 2007-10-10
MX2007008162A (es) 2007-07-24
RU2007125656A (ru) 2009-01-20

Similar Documents

Publication Publication Date Title
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
GB2424581B (en) Formulations
IL186600A0 (en) Novel vaccine formulations
IL177566A0 (en) Pharmaceutical formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
MX2007007613A (es) Formulaciones farmaceuticas.
GB0426301D0 (en) Pharmaceutical formulations
GB0505569D0 (en) Formulations
ZA200604874B (en) Pharmaceutical compositions
GB0416397D0 (en) Pharmaceutical formulations
GB0423800D0 (en) New pharmaceutical formulations
GB0519090D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations
GB0504106D0 (en) Novel formulations
GB0500912D0 (en) Novel formulations
GB0500913D0 (en) Novel formulations
GB0500917D0 (en) Novel formulations
GB0500915D0 (en) Novel formulations
GB0526322D0 (en) Formulations
GB0522917D0 (en) Formulations
GB0520388D0 (en) Formulations
GB0518878D0 (en) Formulations
GB0428010D0 (en) Pharmaceutical formulations
GB0408076D0 (en) Pharmaceutical formulations
GB0408070D0 (en) Pharmaceutical formulations